Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
37 employees
Genetesis: A fast-growing medical imaging firm using data science and biomagnetism to combat heart disease.
HQ
Founded
2013
Founded in 2013, Genetesis is a medical imaging company dedicated to revolutionizing cardiovascular disease diagnosis through advanced data science and biomagnetism. The company's core mission is to provide rapid, non-invasive, and radiation-free diagnostic solutions for detecting myocardial ischemia. Their flagship product, CardioFlux, utilizes magnetocardiography (MCG) to identify functionally significant ischemia at its earliest stages, offering a safer and more efficient alternative to traditional stress testing methods.
Notable affiliates of Genetesis include leading cardiologists and biomedical engineers who contribute to the company's innovative approach. The company has attracted significant investment from venture capital firms focused on healthcare technology. Key achievements include FDA clearance for their CardioFlux system and successful clinical trials demonstrating its efficacy. Genetesis has made a substantial impact on the medical community by providing a faster, safer diagnostic tool, potentially improving outcomes for patients with cardiovascular disease.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Medical Imaging
Technology
Analytics, AI
Tags
Healthtech, Data
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
United States
When was Genetesis founded?
Genetesis was founded in 2013.
Where is Genetesis's headquarters located?
Genetesis's headquarters is located in Cincinnati, OH, US.
When was Genetesis's last funding round?
Genetesis's most recent funding round was for $17.5M (USD) in October 2022.
How many employees does Genetesis have?
Genetesis has 37 employees as of Feb 5, 2024.
How much has Genetesis raised to-date?
As of July 05, 2023, Genetesis has raised a total of $35.8M (USD) since Oct 6, 2022.
Add Comparison
Total Raised to Date
$35.8M
USD
Last Update Oct 6, 2022
Last Deal Details
$17.5M
USD
Oct 6, 2022
Series C
Current Employees
37
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts